Suspension of trading
Intellipharmaceutics International Inc. Share Price
Stocks
I4AA
CA4581733090
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0445 EUR | -13.59% |
|
-.--% | - |
| Market Cap | 15.34L 13.46L 12.54L 11.53L 21.61L 15Cr 21.98L 1.49Cr 58.21L 7.27Cr 57.59L 56.34L 25Cr | P/E 2021 |
-0.4x | P/E 2022 | -0.91x |
|---|---|---|---|---|---|
| Enterprise Value | 37.76L 33.14L 30.86L 28.38L 53.21L 36Cr 54.12L 3.66Cr 1.43Cr 18Cr 1.42Cr 1.39Cr 62Cr | EV / Sales 2021 |
-
| EV / Sales 2022 | 70.8x |
| Free-Float |
98.24% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 day | -13.59% |
| 3 years | 0.03 |  | 0.08 |
| 5 years | 0.01 | | 0.18 |
| 10 years | 0.01 | | 35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Amina Odidi
DFI | Director of Finance/CFO | - | - |
| Comptroller/Controller/Auditor | - | 01/04/2007 | |
| Corporate Officer/Principal | - | 01/02/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Amina Odidi
BRD | Director/Board Member | - | 01/09/2004 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 14/02/24 | Option | Director | 1,00,000 | 0.3022% | ||
| 13/02/24 | Option | Executive/Senior Manager | 2,00,000 | 0.6044% | ||
| 13/02/24 | Option | Director | 1,20,000 | 0.3626% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -13.59% | -.--% | -.--% | -24.58% | 15.18L | |
| +0.31% | +5.25% | +60.43% | +169.28% | 1,08900Cr | |
| +0.40% | +4.80% | +59.36% | +59.91% | 64TCr | |
| +1.39% | +5.27% | +39.45% | +78.27% | 47TCr | |
| -1.16% | +9.51% | +40.27% | +34.52% | 36TCr | |
| -0.94% | +3.33% | +36.74% | +42.22% | 30TCr | |
| +1.06% | +3.54% | +17.87% | +17.58% | 27TCr | |
| +0.89% | +5.48% | -2.85% | -38.29% | 23TCr | |
| +0.04% | +7.74% | +29.92% | +68.43% | 21TCr | |
| -0.79% | +2.29% | +16.72% | +75.11% | 17TCr | |
| Average | -1.22% | +4.46% | +29.79% | +48.24% | 37.31TCr | |
| Weighted average by Cap. | +0.25% | +5.14% | +43.19% | +82.40% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | - | 65.73T 57.68T 53.71T 49.41T 92.61T 62.79L 94.2T 6L 2L 31.14L 2L 2L 1.08Cr |
| Net income | -51.45L -45.15L -42.05L -38.67L -72.5L -49Cr -73.74L -4.99Cr -1.95Cr -24Cr -1.93Cr -1.89Cr -84Cr | -28.92L -25.38L -23.64L -21.74L -40.75L -28Cr -41.45L -2.8Cr -1.1Cr -14Cr -1.09Cr -1.06Cr -47Cr |
| Net Debt | 11.45L 10.05L 9L 9L 16.14L 11Cr 16.42L 1.11Cr 43.47L 5.43Cr 43L 42.07L 19Cr | 22.42L 19.68L 18.32L 16.85L 31.59L 21Cr 32.14L 2.17Cr 85.09L 11Cr 84.18L 82.36L 37Cr |
Employees
11
Sector
Pharmaceuticals
- Stock Market
- Stocks
- I4AA Stock
Select your edition
All financial news and data tailored to specific country editions
